Abstract:OBJECTIVE:To investigate clinical outcomes of ultrasound-guided percutaneous radiofrequency ablation (USG-RFA) in patients with renal clear cell carcinoma.METHODS:Medical records of 34 patients who underwent USG-RFA of renal clear cell carcinoma at the Department of Urology of the Affiliated Drum Tower Hospital of Medical School of Nanjing University from May 2009 to January 2014 were retrospectively reviewed, including 28 male and 6 female patients aged between 25 and 85 years (mean age 60.7 years). Of the included cases, 16 had tumors located in the left kidney, 16 in the right, 1 in the solitary kidney, and 1 in the bilateral kidney. There were 35 tumors in this study totally. The maximum diameter of the tumors was 1.8 to 5.0 cm (mean (2.7 ± 0.3) cm), of which 32 cases of renal tumors were ≤ 4.0 cm and 3 cases of renal tumors were > 4.0 cm to 5.0 cm. Pathological diagnosis were acquired by ultrasound-guided percutaneous biopsy after USG-RFA. Contrast-enhanced ultrasound was used to evaluate tumor outcomes at the time of the surgery, and multi-slice spiral CT enhanced scan and contrast-enhanced ultrasound were used to identify residues and recurrences after treatment.RESULTS:Treatments for all the patients were finished with short postoperative hospital stay about 3-5 days. No complications related to USG-RFA were encountered in any of the cases, such as perirenal fluid collection, perirenal hematoma, and peripheral organ damage. All the cases were diagnosed as clear cell carcinoma according to pathological results. The mean follow-up period was 29 ± 6 (range 3-59) months. Of the 35 USG-RFA-treated subjects, 32 tumors ≤ 4 cm reached the standard of complete treatment after one tumor was found with residue after the first month follow-up, and two tumors were noted recurrence at the 4 and 10 months follow-up after USG-RFA. Nonetheless, no residue or recurrence occurred after secondary treatment for these 3 tumors where pathological diagnosis were acquired again. The other 3 cases with tumors > 4.0 cm to 5.0 cm underwent USG-RFA twice or three times before reaching the standard of complete treatment, of which two had twice and one tumor had three times treatments. There was no carcinoma residue or recurrence during follow-up period.CONCLUSIONS:Percutaneous ultrasound-guided radiofrequency ablation for small renal mass (SRM) has satisfied clinical outcomes, with the advantage of less injury, lower complication rates and shorter recovery time for small size of renal clear cell carcinoma. USG-RFA may become the preferred treatment alternative for SRM.

The Application of Ultrasound-Guided Technology in Percutaneous Radiofrequency Ablation of Renal Tumors

Treatment of Renal Tumors with Ultrasound-Guided Percutaneous Radiofrequency Ablation

Ultrasound-guided Percutaneous Microwave Ablation of Renal Neoplasms

Application of Intraoperative Ultrasonography in Radiofrequency Ablation of Renal Tumors

Ultrasound-guided Percutaneous Microwave Ablation of Bilateral Renal Cell Carcinomas: Focus Upon Safety and Efficacy.

Efficacy of Contrast-Enhanced Ultrasound-Guided Percutaneous Microwave Ablation Treatment of Renal Carcinomas

Efficacy of ultrasound-guided radio-frequency ablation for the treatment of 32 small renal tumors

Ultrasound guided percutaneous microwave ablation for small renal cancer: initial experience.

Application of Contrast-Enhanced Ultrasonography During Radiofrequency Ablation for Renal Tumors

Initial clinical study of ultrasound guided percutaneous microwave ablation treatment for kidney tumors at T1a stage

Percutaneous microwave ablation for renal cell carcinoma：evaluation of therapeutic effect with contrast-enhanced ultrasound

Us-Guided Percutaneous Microwave Ablation of Renal Cell Carcinoma: Intermediate-Term Results

Ultrasound guided percutaneous microwave ablation treatment for renal carcinomas at T1a stage: the safety evaluation in clinical application

Renal tumors: technical success and early clinical experience with radiofrequency ablation of 18 tumors

Assessment of Treatment Efficacy in Radiofrequency Ablation for Renal Tumors by Contrast-Enhanced Ultrasonography

Complications of Ultrasound-Guided Percutaneous Microwave Ablation of Renal Cell Carcinoma.

Role of Contrast-Enhanced Ultrasound in Evaluating the Efficiency of Ultrasound Guided Percutaneous Microwave Ablation in Patients with Renal Cell Carcinoma

Percutaneous Microwave Ablation of Renal Cell Carcinoma: Practice Guidelines of the Ultrasound Committee of Chinese Medical Association, Interventional Oncology Committee of Chinese Research Hospital Association.

[Ultrasound-Guided Percutaneous Radiofrequency Ablation Treatment for Renal Clear Cell Carcinoma].

Ultrasound-Guided Percutaneous Microwave Ablation of Bilateral Renal Cell Carcinoma: A Report of Eight Cases

Percutaneous Microwave Ablation of Renal Cell Carcinoma is Safe in Patients with a Solitary Kidney